Show simple item record

Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial

dc.contributor.authorKulke, M
dc.contributor.authorHorsch, D
dc.contributor.authorCaplin, M
dc.contributor.authorAnthony, L
dc.contributor.authorBergsland, E
dc.contributor.authorOberg, K
dc.contributor.authorWelin, S
dc.contributor.authorWarner, R
dc.contributor.authorLombard-Bohas, C
dc.contributor.authorKunz, P
dc.contributor.authorGrande, E
dc.contributor.authorValle, Juan W
dc.contributor.authorFleming, D
dc.contributor.authorLapuerta, P
dc.contributor.authorBanks, P
dc.contributor.authorJackson, S
dc.contributor.authorWheeler, D
dc.contributor.authorZambrowicz, B
dc.contributor.authorSands, A
dc.contributor.authorPavel, M
dc.date.accessioned2016-04-22T14:57:17Zen
dc.date.available2016-04-22T14:57:17Zen
dc.date.issued2016en
dc.identifier.citationTelotristat Etiprate Shows Benefit in Treating Patients With Carcinoid Syndrome That is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial. 2016, 45(3):478-478 Pancreasen
dc.identifier.urihttp://hdl.handle.net/10541/606636en
dc.language.isoenen
dc.titleTelotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDana-Farber Cancer Institute, Boston, Massen
dc.identifier.journalPancreasen


This item appears in the following Collection(s)

Show simple item record